Background Over one-third of ischaemic strokes occur in the posterior circulation, and a leading cause is atherosclerotic vertebrobasilar disease. Symptomatic vertebrobasilar disease carries a high annual recurrent stroke risk, averaging 10-15% per year. Endovascular angioplasty and stenting are increas-ingly used but carry risks, and the benefit remains unproven. Determining stroke predictors in this population is critical to identifying high-risk patients for future trials of intervention. Preliminary studies indicate that stroke risk in vertebrobasilar disease is strongly related to haemodynamic compromise, which can be measured noninvasively using quantitative magnetic resonance angiography. Methods/study design The Vertebrobasilar Flow Evaluation and Risk of Transient Ischaemic Attack and Stroke (VERiTAS) study, a prospective multicentre NIH-funded observational study of symptomatic vertebrobasilar stenosis (Z50%) or occlusion, is designed to test the hypothesis that patients demonstrating compromised blood flow as assessed by quantitative magnetic resonance angiography are at higher stroke risk. The study will recruit 80 patients at six sites in North America over 4-years. Upon enrollment, subjects will undergo haemodynamic assessment with blinded quantitative magnetic resonance angiography to assess large vessel flow in the vertebrobasilar territory, and be prospectively designated as compromised or normal flow. Patients will be re-imaged with quantitative magnetic resonance angiography at 6-, 12-, and 24-months, and followed for 12-24-months for the primary end-point of stroke in the vertebrobasilar territory. Conclusion: The VERiTAS study is the first prospective study of haemodynamics and stroke risk in the posterior circulation. The results may impact the selection criteria for interventional candidates and also define a low-risk population in whom the risks of invasive interventions would be unnecessary.
Introduction
Posterior circulation strokes account for up to 30-40% of all ischaemic events (1) , an important aetiology of which is atherosclerotic vertebrobasilar disease (VBD). Symptomatic VBD carries a high annual risk of recurrent stroke, averaging 10-15% per year despite medical therapy. Vertebrobasilar stroke is particularly prone to devastating consequences due to the 'eloquence' of the regional brain tissue (2) , and is associated with high rates of death and disability.
VBD and stroke
Large vessel atherosclerotic VBD accounts for approximately one-third of ischaemic events in the posterior circulation territory (3, 4 ). An important stroke mechanism in vertebrobasilar atherostenosis is regional hypoperfusion (5) . Furthermore, both embolic and flow processes can synergise to increase stroke risk; a proposed mechanism is the reduced washout of emboli from the distal circulation in hypoperfused regions (6, 7) . Low flow may also promote local thrombus formation at the site of disease, with resultant stroke (3) . In the setting of hypoperfusion, however, posterior circulation collateral channels such as the posterior communicating arteries may maintain adequate distal flow (8) . The existence and extent of these compensatory blood flow pathways may, therefore, influence the risk of stroke. Haemodynamic impairment has been linked to stroke in the anterior circulation: in carotid occlusion, severe haemodynamic compromise measured by positron emission tomography (PET) and other perfusion modalities predicts subsequent stroke risk (7, 9) . The same role for haemodynamic impairment may be relevant to the posterior circulation, but has not been well examined to date.
Several studies have estimated the recurrent stroke risk associated with vertebrobasilar stenosis (50-99%) to be 10-15% per year (10) (11) (12) (13) . Current medical therapies for cerebrovascular occlusive disease are directed primarily at curtailing the risk of thrombo-embolism (antithrombotic agents) and stabilising plaque (statins, antihypertensives), but do not address an underlying low flow state. Recently, therapies aimed at augmenting blood flow have emerged, primarily in the endovascular arena. Endovascular angioplasty and stenting offer the potential to restore vessel flow and improve haemodynamic compromise. However, these interventions carry significant procedural risk, with periprocedural and 1-year stroke rates ranging from 8% up to 26% in recent series (14) (15) (16) (17) (18) . The benefit from these interventions has not yet been established. Therefore, identification of a high-risk subgroup, owing to haemodynamic impairment, would be important for future trials of intervention.
Haemodynamic assessment in the posterior circulation
Various imaging techniques exist for assessing cerebrovascular haemodynamic compromise, including single photon emission computed tomography, PET, xenon computed tomography (CT), perfusion magnetic resonance (MR) and CT imaging, and transcranial Doppler (TCD). These modalities primarily assess cerebral tissue perfusion, and have proven useful in evaluating anterior circulation flow compromise (7, 9) . However, factors such as inadequate spatial resolution and bony skull base artefacts have rendered them less useful in the posterior circulation, necessitating an alternative strategy. Measurement of large vessel flow in affected and major collateral vessels is one such strategy, and can be obtained noninvasively using the technique of quantitative magnetic resonance angiography (QMRA). The QMRA involves anatomic visualisation of cerebral vessels using time of flight (TOF) imaging, and direct measurement of flow velocity and volume flow rate using phase contrast (PC) imaging. Flow measurement with this technique has demonstrated accuracy in both in vitro and in vivo settings (19, 20) . Commercially available software, noninvasive optimal vessel analysis (NOVA, VasSol Inc., Chicago, IL, USA) uses a standardised TOF and PC MRA protocol to perform cerebrovascular QMRA (21) (22) (23) (24) . In comparison with QMRA, MR perfusion imaging provides tissue-level perfusion data from the brain region of interest. Tissue perfusion has not been well studied in the posterior circulation territory, particularly the brainstem and cerebellum, but may provide important correlative and predictive data for the large vessel conductance flow measured by QMRA. The two imaging modalities can be readily combined to provide both large vessel and tissue level haemodynamic assessment in VBD.
Rationale for the Vertebrobasilar Flow Evaluation and Risk of Transient Ischaemic Attack and Stroke (VERiTAS) study
Retrospective data suggest that QMRA flow measurements have predictive value for subsequent stroke (22) : 48 patients with symptomatic VBD (450% stenosis or occlusion, extracranial or intracranial vertebral or basilar artery) were evaluated based on an algorithm defining flow compromise as 420% reduction below normative lower limits of posterior circulation vessel-specific flow. One-third of patients were characterised as 'low' flow based upon the algorithm, and demonstrated a significantly worse stroke-free survival of 71% (95% CI, 23-92%) at 24-months compared with 100% strokefree survival in the 'normal' flow group. Flow status remained an independent predictor of recurrent stroke after adjusting for stenosis severity and disease location. These data strongly suggest that stroke risk in VBD is determined by the extent of intracranial blood flow compromise, as assessed by QMRA.
Although compelling, retrospective studies have limitations, including the potential for selection bias, recall bias, and ascertainment bias. These can be improved upon with a well-designed and conducted prospective study. Furthermore, it is important to establish that flow measurement QMRA technology is generalisable to a broad range of sites. Therefore, the VERiTAS study is designed as a prospective blinded multicentre observational study to provide high-quality evidence assessing flow status as a stroke predictor in patients with symptomatic VBD.
Study design
Overview The VERiTAS is a multicentre prospective cohort study. Eligible patients undergo MR imaging to assess their cerebrovascular haemodynamic status, the results of which are interpreted centrally and kept blinded from the treating clinicians. The patients are prospectively followed for a minimum of 1year on current standard medical regimen including vascular risk factor modification, statins, and antithrombotic therapy, and evaluated for recurrent ischaemic events.
Study hypotheses
The primary hypothesis is that among patients with symptomatic VBD, those with distal blood flow compromise are at higher risk of subsequent posterior circulation stroke than those with normal flow. Secondary aims of the study are to determine the correlation between large vessel flow and tissue-level perfusion in the posterior circulation, determine other predictive factors for stroke in the target population, evaluate the haemodynamic effects of varying degrees of vertebrobasilar stenosis, examine changes in haemodynamic status of patients on medical therapy over time, and determine the utility of QMRA as a noninvasive screening and monitoring tool for VBD.
Eligibility criteria
Patients presenting with vertebrobasilar distribution transient ischaemic attack (TIA) or stroke are the source group. Symptoms and signs indicative of vertebrobasilar ischaemia are defined as outlined by the Special Report from the National Institute of Neurological Disorders and Stroke (25) . Diagnostic evaluation is performed at the discretion of the treating physicians, but commonly includes: MRA, CT angiography (CTA), TCD or conventional angiography. Patients with evidence of Z50% extracranial or intracranial vertebrobasilar stenosis or occlusion are screened for final eligibility based upon the inclusion/exclusion criteria (Table 1) . Final eligibility requires either CTA or conventional angiographic confirmation; if not performed as standard of care, subjects are asked to consent to craniocervical CTA or two vessel vertebral catheter angiography as part of the research protocol.
Baseline study assessments

Clinical evaluation
The nature and frequency of cerebral ischaemic events are recorded. Medications at the time of enrollment and specific data regarding vascular risk factors are gathered including age, gender, race, hypertension, diabetes mellitus, lipid disorder, coronary disease, smoking, alcohol consumption, and parental death from stroke. Physical examination and neurological evaluation are performed by a study physician. The National Institute of Health Stroke Scale (NIHSS) is administered, and functional status is assessed using the Barthel index, modified Rankin scales, and modified Glasgow outcome score. Available laboratory data including haemoglobin, serum creatinine, lipid profile, homocysteine, high-sensitivity C-reactive protein, haemoglobin-A1c, and casual or fasting plasma glucose are collected, in addition to results of cerebral imaging studies and ancillary testing such as echocardiography and electrocardiography.
MR imaging
A standardised MR imaging protocol consisting of QMRA and MR perfusion is performed within 7-14-days of enrollment. The QMRA portion of the study is performed using NOVA (VasSol Inc.) software, and MR perfusion is performed using dynamic susceptibility contrast (DSC) technique. Imaging consists of axial 3D TOF imaging of the cranial vasculature, from which a 3D image of the vessels is created. Standard sites for flow measurement are chosen from this image in 15 vessels (Fig. 1) ; the locations have been prespecified for consistency between scans and between patients. To minimise the potential effects of turbulent flow, the site for flow measurement is placed at the furthest distance from any existing stenosis within the designated segment. Quantitative flow measurements are then obtained in the chosen vessels using the PC MR technique (24) . Finally, DSC MR perfusion scanning is performed using the magnetic susceptibility contrast bolus tracking method with gradient echo, echo-planar imaging during first passage through the brain of intravenously administered gadolinium contrast (Omniscan, 0Á1 mmol/kg, via 20 G angiocath in antecubital vein using mechanical injector, GE Healthcare, Princeton, NJ, USA). Equivalent protocols for each MR vendor (GE, Milwaukee, WI, USA; Siemens, Malvern, PA, USA; Phillips, Andover, MA, USA) have been specified, with all imaging performed on 3 T machines. The QMRA portion of the study is remotely supervised at the time of imaging by a certified NOVA technician to ensure correct parameters and vessel placement for flow measurement, and the data are automatically transferred via a secure internet-based transfer to the clinical coordinating center (CCC) at the University of Illinois at Chicago (UIC) for central review. The MR perfusion portion of the study is similarly sent for review to the CCC. The imaging results remain blinded to the patient and all participating site personnel. To ensure blinding, the QMRA imaging is permanently removed from the local site workstation after central transfer.
Follow-up study assessments and schedule of visits
Risk factor modifications Treating physicians are encouraged to adhere to published guidelines and use antithrombotic agents, antihypertensive agents, statins, and vascular risk factor control strategies as per published guidelines (26) (27) (28) (29) . Risk factor modification is managed by the study physician in conjunction with the patient's primary care physician or neurologist.
Clinical follow-up evaluations
The patient is contacted monthly by telephone until 12months for the determination of new events using a standardised telephone questionnaire. In-person follow-up is performed at 6-and 12-months at a minimum, and every 6-months thereafter up until completion of the study or 2-years maximum. A detailed neurological evaluation including the standardised assessments (such as NIHSS, Barthel index, etc.) is performed by the blinded study physician, and interval occurrence of any cerebral ischaemic symptoms/signs is noted.
Imaging follow-up
The MR imaging protocol is repeated at 6-and 12-months, and at 24-months if before the completion of the study. Results are centrally reviewed and remain blinded from the participating centre.
End-points
The primary end-point is fatal and nonfatal ischaemic stroke in the vertebrobasilar territory within 12-months. Ischaemic stroke is defined as new neurological symptoms or signs lasting at least 24 h or lasting o24 h but associated with new infarct on CT or MR imaging. Symptoms and signs indicative of vertebrobasilar ischaemia are defined as outlined previously (25) . Secondary end-points are: TIA and ischaemic stroke in the vertebrobasilar territory; ischaemic stroke in any vascular territory; all ischaemic stroke and vascular death (death from a vascular aetiology or sudden death not explained by a known nonvascular process); aggregate of any ischaemic stroke, myocardial infarction, and vascular death; all stroke (ischaemic and haemorrhagic); all death; neurological impairment as determined by the NIHSS; neurological disability as determined by the modified Barthel index; and handicap as determined by the modified Rankin scale.
When a potential end-point is identified, the study personnel arrange for the patient to be evaluated by the blinded study physician within 72 h. Initial end-point determinations are made by the participating site but the relevant information is submitted to the CCC for final adjudication by an independent panel of two vascular neurologists, blinded to the patient's study protocol imaging results. If the opinions of the two adjudicators differ, a third adjudicator is consulted for majority opinion.
Data management
All clinical data are submitted to the Data Management Center (DMC) at UIC via a secure web-based data entry system. All study imaging data are centrally reviewed to confirm adequate imaging quality and completeness. Data from the MR perfusion portion of the imaging are analysed for the calculation of regional perfusion parameters (tissue transit time, time to arrival, and cerebral blood volume). Initial determination of vertebral or basilar stenosis for eligibility is made locally at the participating centre using the WASID technique (30) . Relevant angiographic images are sent to the CCC, and reviewed by a blinded neuroradiologist for final determination of degree of stenosis.
Sample size estimates
Event rates were estimated from published preliminary data (22) , which indicated a 71% 1-year stroke-free survival in symptomatic VBD patients designated as low flow, translating into an annual event rate of 29%. There was a 0% stroke and 4% TIA rate in the normal flow group; consequently, a conservative estimate of 2% stroke event rate was used for this group. The data also indicated that recruitment into the normal vs. low flow group would occur at a 2 : 1 ratio. Sample sizes were calculated for a range of possible event rates in the low flow group from 18% to 28%, assuming a 2 : 1 proportion of normal : low flow. A ten percent attrition rate was included. Based upon these assumptions, a sample size of 80 patients achieves 80% power in detecting a significant difference between an annual event rate of 22% in the low flow group and 2% in the normal flow group, and at least 50% power for detecting a difference even if the event rate in the low flow group is as low as 13%.
Statistical analysis
Analysis of the primary end-point (ischaemic stroke in the vertebrobasilar territory) will be a time-to-event comparison using the log-rank test between subjects designated as low vs. normal flow, based upon the subject's initial enrollment QMRA study (using parameters defined in our preliminary studies) (22) . Subjects will be censored at the time of any endovascular or surgical revascularisation procedures, or at the end of the follow-up period. Exploration for risk factors and adjustment for covariates will be performed with Cox's proportional hazards analysis. Post hoc sensitivity analysis will examine alternative cut-points for the designation of low or normal flow status, to determine if an 'optimised' flow algorithm can be generated with greater sensitivity/specificity in stroke prediction. Correlation analyses will be performed to assess the linear relationships between perfusion parameters and large vessel flow measurements. The sensitivity analysis performed to examine varying cut-points for large vessel flows will also be performed with integration of the MR perfusion data.
Organisation
The organisational elements of VERiTAS study group are listed in the appendix, and consist of the CCC, DMC, participating sites, and committees (Operations Committees, Advisory committee, Adjudication Committee, and Angiography Review Committee).
Conclusion
The VERiTAS is the first prospective study of haemodynamics and stroke risk in the posterior circulation. The results may impact the selection criteria and likelihood for success of future clinical trials aimed at assessing the efficacy of endovascular or surgical interventions for VBD. Moreover, defining a low-risk population in whom the risks of invasive interventions would be unnecessary would have an equally important impact on VBD management, both from a clinical, and cost perspective. The data regarding the haemodynamic effects of VBD, and their temporal progression, may also enhance our understanding of the basic pathophysiology and mechanisms of stroke in this morbid disease entity.
